Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes
YF Liu(Loma Linda University Medical Center), Timothy Tree(King's College London), Leena Khatri(King's College London), Evangelia Williams(King's College London), Mamta Joshi(Guy's and St Thomas' NHS Foundation Trust), Loïc Lhuillier(King's College London), Anna Lorenc(Guy's and St Thomas' NHS Foundation Trust), Jennie H. M. Yang(Mayo Clinic), Mark Peakman(Sanofi (France)), Craig A. Beam(Western Michigan University), Emma Smith(UCB Pharma (United Kingdom)), Jake Powrie(Guy's and St Thomas' NHS Foundation Trust), Nikolaos Fountoulakis(Guy's and St Thomas' NHS Foundation Trust), Sefina Arif(Guy's Hospital)
Cited by 1
Related Papers
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes
|Nature Genetics|2007|1.5k
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
|The Lancet Oncology|2021|614
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes
|Diabetes Care|2019|350